1. Market Research
  2. > Bleeding And Clotting Disorders – Pipeline Review, H1 2013

Bleeding And Clotting Disorders – Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 345 pages

Bleeding And Clotting Disorders – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Bleeding And Clotting Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bleeding And Clotting Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bleeding And Clotting Disorders. Bleeding And Clotting Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bleeding And Clotting Disorders.
- A review of the Bleeding And Clotting Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bleeding And Clotting Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bleeding And Clotting Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bleeding And Clotting Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bleeding And Clotting Disorders - Pipeline Review, H1 2013
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Bleeding And Clotting Disorders Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Bleeding And Clotting Disorders 12
Bleeding And Clotting Disorders Therapeutics under Development by Companies 14
Bleeding And Clotting Disorders Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 22
Comparative Analysis 22
Mid Clinical Stage Products 23
Comparative Analysis 23
Early Clinical Stage Products 24
Comparative Analysis 24
Discovery and Pre-Clinical Stage Products 25
Comparative Analysis 25
Bleeding And Clotting Disorders Therapeutics - Products under Development by Companies 26
Bleeding And Clotting Disorders Therapeutics - Products under Investigation by Universities/Institutes 34
Companies Involved in Bleeding And Clotting Disorders Therapeutics Development 35
Baxter International Inc. 35
Johnson and Johnson 36
Kyowa Hakko Kirin Co., Ltd. 37
Biogen Idec Inc. 38
Nektar Therapeutics 39
Isis Pharmaceuticals, Inc. 40
Biotest AG 41
Cangene Corporation 42
Lentigen Corporation 43
Sangamo BioSciences, Inc. 44
Pharming Group N.V. 45
Novo Nordisk A/S 46
BioLineRx, Ltd. 47
Apitope International NV 48
Novartis AG 49
BioMarin Pharmaceutical Inc. 50
Chugai Pharmaceutical Co. Ltd 51
Dong-A Pharmaceutical Co., Ltd. 52
Glenmark Pharmaceuticals Ltd. 53
GTC Biotherapeutics, Inc. 54
Octapharma AG 55
Pain Therapeutics, Inc. 56
Pfizer Inc. 57
Bayer AG 58
Living Cell Technologies Limited 59
PROLOR Biotech, Inc. 60
ReGenX Biosciences, LLC 61
Orchid Chemicals and Pharmaceuticals Ltd 62
Alnylam Pharmaceuticals, Inc 63
Portola Pharmaceuticals, Inc. 64
Flamel Technologies S.A. 65
CSL Limited 66
Green Cross Holdings Corporation 67
Catalyst Biosciences, Inc. 68
NanoCarrier Co., Ltd. 69
Curacyte AG 70
Endotis Pharma 71
ProFibrix, BV. 72
Recoly N.V. 73
Amarna Therapeutics B.V. 74
Asahi Kasei Pharma 75
EpiVax, Inc. 76
ARCA biopharma, Inc. 77
Thrombotargets Corporation 78
NovaLead Pharma Pvt. Ltd. 79
Haemostatix Ltd 80
QRxPharma Limited 81
Omeros Corporation 82
Expression Therapeutics LLC 83
BioStar Pharmaceuticals, Inc. 84
Bio Products Laboratory 85
Asklepios BioPharmaceutical, Inc. 86
REGiMMUNE Corporation 87
China Biologic Products, Inc. 88
Amunix, Inc. 89
LFB Biotechnologies, S.A.S.U. 90
Ascendis Pharma A/S 91
PolyTherics Limited 92
PepTx, Inc. 93
Celtic Pharmaceutical Holdings L.P. 94
Laboratorio Elea S.A.C.I.F. and A 95
Bleeding And Clotting Disorders - Therapeutics Assessment 96
Assessment by Monotherapy Products 96
Assessment by Route of Administration 97
Assessment by Molecule Type 99
Drug Profiles 102
turoctocog alfa - Drug Profile 102
Long-Lasting rFactor VIII - Drug Profile 104
Factor IX Gene Therapy - Drug Profile 106
OBI-1 - Drug Profile 107
rivaroxaban - Drug Profile 109
Q-8009 - Drug Profile 113
Q-8008 - Drug Profile 114
Recombinant Human Fibrinogen - Drug Profile 115
TT-105 - Drug Profile 116
TT-111 - Drug Profile 117
TT-112 - Drug Profile 118
TT-173 - Drug Profile 119
beroctocog alfa - Drug Profile 120
beroctocog alfa - Drug Profile 122
CSL-689 - Drug Profile 124
Recombinant Coagulation Factors - Drug Profile 126
EP-5001 - Drug Profile 127
fondaparinux sodium - Drug Profile 128
Blood Clotting Factors - Drug Profile 129
BAX-855 - Drug Profile 130
TT-120 - Drug Profile 131
thrombomodulin alfa - Drug Profile 132
Factor IX - Drug Profile 134
ZFP TFs For Hemophilia - Drug Profile 135
NU-172 - Drug Profile 136
hcl-rFVIII - Drug Profile 138
LG-889 - Drug Profile 140
ATX-F8 - Drug Profile 141
Certoparin - Drug Profile 142
BAX-826 - Drug Profile 143
Long-Lasting rFactor IX - Drug Profile 144
Long-Lasting rFactor IX - Drug Profile 145
catridecacog - Drug Profile 146
catridecacog - Drug Profile 148
Q-8010 - Drug Profile 150
KW-3357 - Drug Profile 151
KW-3357 - Drug Profile 152
oprelvekin - Drug Profile 153
EP-217609 - Drug Profile 154
BAY-818973 - Drug Profile 156
PRT-4445 - Drug Profile 158
trenonacog alfa - Drug Profile 159
trenonacog alfa - Drug Profile 161
PF-05280602 - Drug Profile 163
Hemophilia A Gene Therapy - Drug Profile 164
epoetin alfa - Drug Profile 165
carvedilol - Drug Profile 166
GBR-600 - Drug Profile 167
Human Coagulation Factor X - Drug Profile 168
Plasmin And Plasma Kallikrein Inhibitor - Drug Profile 169
vonicog alfa - Drug Profile 170
CSL-654 - Drug Profile 171
NN-7088 - Drug Profile 173
AAV2-hFIX - Drug Profile 174
NN-7999 - Drug Profile 175
BAX-326 - Drug Profile 176
BAX-326 - Drug Profile 178
NN-7415 - Drug Profile 180
ISIS-FXIRx - Drug Profile 181
NLP-91 - Drug Profile 182
Drug For Hemophilia B - Drug Profile 183
BAY-949027 - Drug Profile 184
BAX-513 - Drug Profile 185
IB1-007 - Drug Profile 186
IB1-008 - Drug Profile 187
DA-3808 - Drug Profile 188
MOD-9017 - Drug Profile 189
HM-12260B - Drug Profile 190
OMS-616 - Drug Profile 191
Recombinant Factor VIIa - Drug Profile 193
PEG-rFVIII-PI Complex - Drug Profile 195
Longer Acting Therapeutic Clotting Proteins - Drug Profile 196
ALN-APC Program - Drug Profile 197
MOD-5017 - Drug Profile 198
CSL-627 - Drug Profile 199
Human Coagulation Factor-VIII - Drug Profile 200
bivalirudin - Drug Profile 201
Human Plasma Proteins - Drug Profile 202
ISIS-FVIIRx - Drug Profile 204
Deimmunized FVIII - Drug Profile 205
Human Fibrinogen - Drug Profile 206
CSL-650 - Drug Profile 207
Octafibrin - Drug Profile 208
Gene Therapy For Hemophilia A - Drug Profile 209
EDP-27 - Drug Profile 210
Factor-VIII - Drug Profile 211
Factor VIIa - Drug Profile 212
Factor IX - Drug Profile 213
desmopressin acetate - Drug Profile 214
Long Acting Blood Coagulation Factor IX - Drug Profile 215
Long Acting Coagulation Factor VIIa - Drug Profile 216
AB-022 - Drug Profile 218
ALN-AT3 - Drug Profile 219
rhFactor VIII - Drug Profile 220
Human Prothrombin Complex Concentrate - Drug Profile 221
Gene Therapy for Hemophilia A - Drug Profile 222
beroctocog alfa - Drug Profile 223
beroctocog alfa - Drug Profile 224
Fac8Cell - Drug Profile 225
PTX-003 - Drug Profile 226
ACE-910 - Drug Profile 227
HDFx - Drug Profile 228
PeproStat - Drug Profile 229
BNP-FVIII - Drug Profile 230
HXTC-901 - Drug Profile 231
HaemoPlax - Drug Profile 232
NAVOH-002 - Drug Profile 233
Zhixuening Pian - Drug Profile 234
Fibrin-Pad - Drug Profile 235
BAX-817 - Drug Profile 237
Protein Micelle - Drug Profile 239
RGI-5000 - Drug Profile 240
NBP-604 - Drug Profile 241
NBP-611 - Drug Profile 242
NBP-603 - Drug Profile 243
Drug For Bleeding Disorders And Cancer - Drug Profile 244
V-0801 - Drug Profile 245
Fibrinogen - Drug Profile 246
DIS-COM-COAG - Drug Profile 247
Recombinant Simukunin - Drug Profile 248
Factor VIII Gene Therapy Program - Drug Profile 249
TheraPEG-FVIII - Drug Profile 250
Recombinant Factor IX - Drug Profile 251
Recombinant Factor Xa - Drug Profile 252
Rec Fibrinogen Injectable Hemostat - Drug Profile 253
MT-026 - Drug Profile 254
MT-033 - Drug Profile 255
Vicagrel - Drug Profile 256
eptacog alfa biosimilar - Drug Profile 257
moroctocog alfa Biosimilar - Drug Profile 258
PER-977 - Drug Profile 259
TheraPEG Factor IX - Drug Profile 260
TheraPEG Factor VIIa - Drug Profile 261
Drug Targeting Thrombin - Drug Profile 262
Fibrin Blocking Peptides - Drug Profile 263
Peptide Mimetic - Drug Profile 264
rFVIII - Drug Profile 265
Factor XIa Inhibitors - Drug Profile 266
eptacog alfa biobetter - Drug Profile 267
Bleeding And Clotting Disorders Therapeutics - Drug Profile Updates 268
Bleeding And Clotting Disorders Therapeutics - Discontinued Products 318
Bleeding And Clotting Disorders Therapeutics - Dormant Products 320
Bleeding And Clotting Disorders - Product Development Milestones 325
Featured News and Press Releases 325
Appendix 334
Methodology 334
Coverage 334
Secondary Research 334
Primary Research 334
Expert Panel Validation 334
Contact Us 335
Disclaimer 335

List of Tables

Number of Products Under Development for Bleeding And Clotting Disorders, H1 2013 22
Products under Development for Bleeding And Clotting Disorders - Comparative Analysis, H1 2013 23
Number of Products under Development by Companies, H1 2013 25
Number of Products under Development by Companies, H1 2013 (Contd..1) 26
Number of Products under Development by Companies, H1 2013 (Contd..2) 27
Number of Products under Development by Companies, H1 2013 (Contd..3) 28
Number of Products under Development by Companies, H1 2013 (Contd..4) 29
Number of Products under Investigation by Universities/Institutes, H1 2013 31
Comparative Analysis by Late Stage Development, H1 2013 32
Comparative Analysis by Mid Clinical Stage Development, H1 2013 33
Comparative Analysis by Early Clinical Stage Development, H1 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 35
Products under Development by Companies, H1 2013 36
Products under Development by Companies, H1 2013 (Contd..1) 37
Products under Development by Companies, H1 2013 (Contd..2) 38
Products under Development by Companies, H1 2013 (Contd..3) 39
Products under Development by Companies, H1 2013 (Contd..4) 40
Products under Development by Companies, H1 2013 (Contd..5) 41
Products under Development by Companies, H1 2013 (Contd..6) 42
Products under Development by Companies, H1 2013 (Contd..7) 43
Products under Investigation by Universities/Institutes, H1 2013 44
Baxter International Inc., H1 2013 45
Johnson and Johnson, H1 2013 46
Kyowa Hakko Kirin Co., Ltd., H1 2013 47
Biogen Idec Inc., H1 2013 48
Nektar Therapeutics, H1 2013 49
Isis Pharmaceuticals, Inc., H1 2013 50
Cangene Corporation, H1 2013 52
Lentigen Corporation, H1 2013 53
Sangamo BioSciences, Inc., H1 2013 54
Pharming Group N.V., H1 2013 55
Novo Nordisk A/S, H1 2013 56
BioLineRx, Ltd., H1 2013 57
Apitope International NV, H1 2013 58
Novartis AG, H1 2013 59
BioMarin Pharmaceutical Inc., H1 2013 60
Chugai Pharmaceutical Co. Ltd, H1 2013 61
Dong-A Pharmaceutical Co., Ltd., H1 2013 62
Glenmark Pharmaceuticals Ltd., H1 2013 63
GTC Biotherapeutics, Inc., H1 2013 64
Octapharma AG, H1 2013 65
Pain Therapeutics, Inc., H1 2013 66
Pfizer Inc., H1 2013 67
Bayer AG, H1 2013 68
Living Cell Technologies Limited, H1 2013 69
PROLOR Biotech, Inc., H1 2013 70
ReGenX Biosciences, LLC, H1 2013 71
Orchid Chemicals and Pharmaceuticals Ltd, H1 2013 72
Alnylam Pharmaceuticals, Inc, H1 2013 73
Portola Pharmaceuticals, Inc., H1 2013 74
Flamel Technologies S.A., H1 2013 75
CSL Limited, H1 2013 76
Green Cross Holdings Corporation, H1 2013 77
Catalyst Biosciences, Inc., H1 2013 78
NanoCarrier Co., Ltd., H1 2013 79
Curacyte AG, H1 2013 80
Endotis Pharma, H1 2013 81
ProFibrix, BV., H1 2013 82
Amarna Therapeutics B.V., H1 2013 84
Asahi Kasei Pharma, H1 2013 85
EpiVax, Inc., H1 2013 86
ARCA biopharma, Inc., H1 2013 87
Thrombotargets Corporation, H1 2013 88
NovaLead Pharma Pvt. Ltd., H1 2013 89
Haemostatix Ltd, H1 2013 90
QRxPharma Limited, H1 2013 91
Omeros Corporation, H1 2013 92
Expression Therapeutics LLC, H1 2013 93
BioStar Pharmaceuticals, Inc., H1 2013 94
Bio Products Laboratory, H1 2013 95
Asklepios BioPharmaceutical, Inc., H1 2013 96
REGiMMUNE Corporation, H1 2013 97
China Biologic Products, Inc., H1 2013 98
Amunix, Inc., H1 2013 99
LFB Biotechnologies, S.A.S.U., H1 2013 100
Ascendis Pharma A/S, H1 2013 101
PolyTherics Limited, H1 2013 102
PepTx, Inc., H1 2013 103
Celtic Pharmaceutical Holdings L.P., H1 2013 104
Laboratorio Elea S.A.C.I.F. and A, H1 2013 105
Assessment by Monotherapy Products, H1 2013 106
Assessment by Stage and Route of Administration, H1 2013 108
Assessment by Stage and Molecule Type, H1 2013 111
Bleeding And Clotting Disorders Therapeutics - Drug Profile Updates 278
Bleeding And Clotting Disorders Therapeutics - Discontinued Products 328
Bleeding And Clotting Disorders Therapeutics - Discontinued Products (Contd..1) 329
Bleeding And Clotting Disorders Therapeutics - Dormant Products 330
Bleeding And Clotting Disorders Therapeutics - Dormant Products (Contd..1) 331
Bleeding And Clotting Disorders Therapeutics - Dormant Products (Contd..2) 332
Bleeding And Clotting Disorders Therapeutics - Dormant Products (Contd..3) 333
Bleeding And Clotting Disorders Therapeutics - Dormant Products (Contd..4) 334

List of Figures

Number of Products under Development for Bleeding And Clotting Disorders, H1 2013 22
Products under Development for Bleeding And Clotting Disorders - Comparative Analysis, H1 2013 23
Products under Development by Companies, H1 2013 24
Products under Investigation by Universities/Institutes, H1 2013 30
Late Stage Products, H1 2013 32
Mid Clinical Stage Products, H1 2013 33
Early Clinical Stage Products, H1 2013 34
Discovery and Pre-Clinical Stage Products, H1 2013 35
Assessment by Monotherapy Products, H1 2013 106
Assessment by Route of Administration, H1 2013 107
Assessment by Stage and Route of Administration, H1 2013 108
Assessment by Molecule Type, H1 2013 109
Assessment by Stage and Molecule Type, H1 2013 110

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.